NCT02112032View on ClinicalTrials.gov

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 24, 2014

Primary Completion Date

April 12, 2019

Study Completion Date

July 17, 2020

Conditions
Melanoma
Interventions
DRUG

MK-3475

This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.

DRUG

Peginterferon alfa-2b

This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Melanoma Research Alliance

OTHER

lead

Hassane M. Zarour, MD

OTHER